BCL2 and lymphoma: As demonstrated in Figure 3g, Raji-4RH and RL-4RH lymphomas do not express Bcl-2 and, for this reason, ABT-263 treatment resulted inefficacious, either as a single agent or in combination, even at high micromolar doses (Supplementary Figure S4).